{"product_id":"phocabo-80-cabozantinib","title":"POMMADX 2 (Pomalidomide)","description":"\u003ch2\u003eAbout Pomalidomide\u003c\/h2\u003e\u003cp\u003ePomalidomide is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. Pomalidomide directly inhibits angiogenesis and myeloma cell growth. This dual effect is central to its activity in myeloma, rather than other pathways such as TNF alpha inhibition, since potent TNF inhibitors including rolipram and pentoxifylline do not inhibit myeloma cell growth or angiogenesis.\u003csup id=\"cite_ref-pmid11740816_18-1\" class=\"reference\"\u003e\u003c\/sup\u003e Upregulation of interferon gamma, IL-2 and IL-10 as well as downregulation of IL-6 have been reported for pomalidomide. These changes may contribute to pomalidomide's anti-angiogenic and anti-myeloma activities.\u003csup id=\"cite_ref-Pomalyst_PI_7-2\" class=\"reference\"\u003e\u003c\/sup\u003e\u003c\/p\u003e\u003ch2\u003eMultiple Myeloma\u003c\/h2\u003e\u003cp\u003eIndicated in combination with dexamethasone, for multiple myeloma (MM) in patients who have received at least 2 prior therapies (including lenalidomide and a proteasome inhibitor) and have disease progression on or within 60 days of completion of the last therapy\u003c\/p\u003e\u003cp\u003e4 mg PO qDay on Days 1-21 of repeated 28-day cycles until disease progression; give in combination with low-dose dexamethasone\u003c\/p\u003e\u003ch3\u003eLow-dose dexamethasone\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eGive PO only on Days 1, 8, 15, and 22 of each 28-day cycle\u003c\/li\u003e\n\u003cli\u003e≤75 years: 40 mg\/day\u003c\/li\u003e\n\u003cli\u003e\u0026gt;75 years: 20 mg\/day\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eKaposi Sarcoma\u003c\/h2\u003e\u003ch3\u003eAIDS-related Kaposi sarcoma (KS)\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eIndicated for AIDS-related KS in patients who failed highly active antiretroviral therapy (HAART)\u003c\/li\u003e\n\u003cli\u003e5 mg PO qDay on Days 1-21 of each 28-day cycle\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003cli\u003eContinue HAART as HIV treatment\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eKS in adults who are HIV-negative\u003c\/h3\u003e\u003cul\u003e\n\u003cli\u003eIndicated for KS in adults who are HIV-negative\u003c\/li\u003e\n\u003cli\u003e5 mg PO qDay on Days 1-21 of each 28-day cycle\u003c\/li\u003e\n\u003cli\u003eContinue until disease progression or unacceptable toxicity\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BIGBEAR Pharma, Laos PDR","offers":[{"title":"Default Title","offer_id":44797946363947,"sku":"RL2820240912262","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-09-1192.jpg?v=1787022073","url":"https:\/\/xomeds.com\/products\/phocabo-80-cabozantinib","provider":"XOMEDS","version":"1.0","type":"link"}